• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
LIU Na,LIU Renhan,SHI Luping,MA Yan,PU Hongli.Exploring the protective effect of ligustilide derivatives on H9C2 cell OGD/R injury model based on Nrf2/HO-1 signaling pathway[J].Journal Of Pharmaceutical Research,2026,45(1):22-26[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 2799times   Download 870次 QR Code for this article
Scan with your phone!
基于Nrf2/HO-1信号通路探讨藁本内酯衍生物对H9c2细胞OGD/R损伤模型的保护作用
柳娜1,刘仁憨1,石露萍2,马燕3,蒲红利1
Font:Larger+|Default|Smaller-
(1.天水师范大学,甘肃 天水 741001;2.新疆第二医学院,新疆 克拉玛依 834000;3.甘肃省中医院,甘肃 兰州 730050)
摘要:
目的 探讨藁本内酯衍生物环丙藁本(LIGc)对H9c2细胞氧糖剥夺/复氧(OGD/R)损伤的影响及作用机制。方法 以H9c2细胞为研究对象,将细胞分为空白组、OGD/R模型组、LIGc组,采用细胞增殖与毒性试剂盒(CCK-8)检测细胞活率;采用微孔板法检测细胞中一氧化氮(NO)、丙二醛(MDA)、SOD(超氧化物歧化酶)、GSH(谷胱甘肽)和乳酸脱氢酶(LDH)含量;采用流式细胞仪分析细胞中活性氧(ROS)水平和细胞凋亡率;运用免疫印迹(WB)技术测定细胞内核因子红系2相关因子2(Nrf2)、血红素氧合酶-1(HO-1)、B细胞淋巴瘤-2(Bcl-2)与Bcl-2相关X蛋白(Bax)蛋白表达。结果 与空白组相比,模型组细胞活性显著降低(P<0.01),氧化应激(NO、MDA、ROS 升高,SOD、GSH 降低)及凋亡(Bax/Bcl-2 比值升高)加剧(P<0.01)。LIGc 干预可显著逆转上述变化(P<0.01 或 P<0.05。结论 中药当归药效标志物藁本内酯结构衍生物LIGc能减轻氧糖剥夺/复氧诱导的H9c2氧化应激损伤,其作用机制可能与调节Nrf2/HO-1信号通路有关。
关键词:  藁本内酯  结构衍生物  氧糖剥夺/复氧损伤  氧化应激  细胞凋亡
DOI:10.13506/j.cnki.jpr.2026.01.004
基金项目:天水师范学院科研项目(No.tsnu0225026);2025年高校教师创新基金项目(No.2025A-144);“2024年甘肃省高等学校教育教学成果培育项目”阶段性成果;2024年天水师范学院校列科研项目(No.YXZ2024-03);2025年天水师范学院教育教学改革研究项目
Publication Date:January 26, 2026
Exploring the protective effect of ligustilide derivatives on H9C2 cell OGD/R injury model based on Nrf2/HO-1 signaling pathway
LIU Na1,LIU Renhan1,SHI Luping2,MA Yan3,PU Hongli1
(1.Tianshui Normal University,Tianshui 741001,China;2.Xinjiang Second Medical College,Karamay 834000,China;3.Gansu Provincial Hospital of Traditional Chinese Medicine,Lanzhou 730050,China)
Abstract:
Objective To investigate the effects and mechanisms of ligustilide derivative cyclopropyl-ligustilide (LIGc) on oxygen-glucose deprivation/reoxygenation (OGD/R)-induced injury in H9c2 cells. Methods H9c2 cells were divided into control, OGD/R model, and LIGc-treated groups. Cell viability was assessed using the Cell Counting Kit-8 (CCK-8). Microplate assays were employed to measure nitric oxide (NO), malondialdehyde (MDA), superoxide dismutase (SOD), glutathione (GSH), and lactate dehydrogenase (LDH) levels. Flow cytometry was used to detect reactive oxygen species (ROS) levels and apoptosis rate. Western blot (WB) analyzed protein expression of nuclear factor erythroid 2-related factor 2 (Nrf2), heme oxygenase-1 (HO-1), B-cell lymphoma-2 (Bcl-2), and Bcl-2-associated X protein (Bax). Results Compared with the control group, the OGD/R model group exhibited significantly reduced cell viability (P<0.01), aggravated oxidative stress (elevated NO, MDA, ROS; decreased SOD, GSH), and increased apoptosis (elevated Bax/Bcl-2 ratio) (all P<0.01). LIGc treatment markedly reversed these alterations (P<0.01 or P<0.05). Conclusion The ligustilide derivative LIGc, a bioactive marker of Angelica sinensis, alleviates OGD/R-induced oxidative stress injury in H9c2 cells, potentially through regulating the Nrf2/HO-1 signaling pathway.
Key words:  Ligustilide  Structural derivatives  Oxygen glucose deprivation/reoxygenation injury  Oxidative stress  Cell apoptosis
Today's Visits:447    Total Visits:2383131
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.